Johncilla M, et al. - In this study, gastric biopsies from individuals on immune checkpoint inhibitor therapy with clinical suspicion of drug-associated gastrointestinal injury were recognized in order to identify the histologic characteristics of immune checkpoint inhibitor therapy-related gastritis. Twelve persons involved in the study group were administered ipilimumab, nivolumab or pembrolizumab for various types of tumors. Symptoms at presentation were nausea, vomiting, and diarrhea. In 8/12 individuals, chronic active gastritis with intraepithelial lymphocytosis and prominent apoptosis was observed and was the most beneficial combination for the diagnosis of drug-induced gastritis in these cases. Ten individuals responded to medication withdrawal and steroid therapy whilst two needed treatment with infliximab. Thus, for accurate diagnosis and prompt management of these cases, knowledge of the morphological spectrum of immune checkpoint inhibitor therapy-related gastritis is significant.